Search
  • 5251793

RiboPro raises €1.2M to become leader in (m)RNA

Monday 22 March 2021, Oss, the Netherlands – RiboPro announced it has successfully closed a funding round of €1.2 million, led by Stichting Vlasroot, with a consortium of BOM, Rockstart and several private investors contributing to this round.

The new funding will be used to advance RiboPro’s proprietary messenger RNA (mRNA) technology, strengthen the team, and scale the business. With its high-performance RNA products RiboPro supports researchers and medicine developers worldwide in the adoption of the promising mRNA technology.

“We are excited to have such a strong consortium of investors come on-board, supporting our mission to accelerate the adoption of mRNA as ingredient in life-changing medicines, pandemic-curbing vaccines and state-of-the-art research. We envision mRNA to play a crucial role in the bio-based medical revolution that has just started and will deliver a better life for many. With this new round, we feel, more than ever, ready to play our part in that“, says Sander van Asbeck, CEO and founder of RiboPro.

Vlasroot is privileged to help RiboPro in its mission to become a leading player in the field of mRNA products globally. The current COVID-19 messenger RNA vaccines have shown the potential of the technology where mRNA has ripped up conventional timelines to start testing within weeks. We strongly believe that mRNA will change the industry forever and it is exciting to be part of that change.” Roel Elshout from Vlasroot adds.

RiboPro lifts mRNA to the next level, increasing the activity of mRNA while decreasing its toxicity and immunogenic response. Potential applications of RiboPro’s mRNA are numerous both in research, tissue engineering and in therapeutics. We are proud to be part of this journey, and look forward to working with the team to make RiboPro a global provider of top quality mRNA.“ says Mercedes Tuin, Senior Investment Manager, BOM.

The early success of the COVID-19 mRNA vaccines demonstrates the future potential of mRNA. Rockstart has recognized the promise of mRNA and believes that more and more researchers and pharmacists will show their interest in the technique. This heralds a new era for the application of mRNA and RiboPro can respond perfectly to this.” says Tonko Wedda, Director, Rockstart Health.


3 views0 comments